Martin Fan
Stock Analyst at Wedbush
(4.73)
# 132
Out of 5,126 analysts
18
Total ratings
76.47%
Success rate
49.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Maintains: Outperform | $42 → $45 | $33.05 | +36.16% | 2 | Jan 13, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Outperform | $45 | $21.80 | +106.42% | 3 | Dec 22, 2025 | |
| VOR Vor Biopharma | Assumes: Neutral | $9 | $13.16 | -31.61% | 1 | Nov 25, 2025 | |
| IMA ImageneBio | Assumes: Underperform | $2 | $7.02 | -71.49% | 1 | Nov 25, 2025 | |
| ANAB AnaptysBio | Reiterates: Outperform | $50 | $49.73 | +0.54% | 5 | Nov 24, 2025 | |
| SANA Sana Biotechnology | Maintains: Outperform | $5 → $6 | $3.93 | +52.67% | 2 | Nov 7, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Outperform | $18 → $23 | $4.03 | +470.72% | 2 | Oct 17, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $6.49 | +485.52% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $3.57 | +124.09% | 1 | May 28, 2025 |
Oruka Therapeutics
Jan 13, 2026
Maintains: Outperform
Price Target: $42 → $45
Current: $33.05
Upside: +36.16%
Zenas BioPharma
Dec 22, 2025
Reiterates: Outperform
Price Target: $45
Current: $21.80
Upside: +106.42%
Vor Biopharma
Nov 25, 2025
Assumes: Neutral
Price Target: $9
Current: $13.16
Upside: -31.61%
ImageneBio
Nov 25, 2025
Assumes: Underperform
Price Target: $2
Current: $7.02
Upside: -71.49%
AnaptysBio
Nov 24, 2025
Reiterates: Outperform
Price Target: $50
Current: $49.73
Upside: +0.54%
Sana Biotechnology
Nov 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $3.93
Upside: +52.67%
Artiva Biotherapeutics
Oct 17, 2025
Maintains: Outperform
Price Target: $18 → $23
Current: $4.03
Upside: +470.72%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $6.49
Upside: +485.52%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $3.57
Upside: +124.09%